Author(s): Ventola CL
Abstract Share this page
Abstract Before the FDA can set up safety guidelines for nanomedicines, it needs to establish valid testing criteria. The goal is to strike a balance between underregulation (which can lead to questionable approvals) and overregulation (which can inhibit innovation).
This article was published in P T
and referenced in Journal of Bioequivalence & Bioavailability